Avid Bioservices Inc (CDMO)

[until2000]

I think there will be more news reported tomorrow. It implies it in the abstract:

"...All responses were confirmed at least 4 weeks later. Conclusions: Bavituximab plus docetaxel achieved an encouraging response rate in advanced/metastatic breast cancer in Stage A of this study. Enrollment in Stage B of the trial is expected to be completed with preliminary results available by the annual meeting. "

I hope they do include preliminary results. More patients, and hopefully more successes.